Skip to main content
AmigoFish

151: Why Retatrutide May Outperform GLP-1 Drugs

From Ben Bikman · · 26 min

The player loads from YouTube only when you click. It uses YouTube's privacy-enhanced mode.

If the video does not play, the owner may have turned off embedding. Watch it on YouTube instead.

Watch on YouTube

Not rated yet

Description

📢 Ask Dr. Bikman’s Digital Mind (multilingual): https://benbikman.com/ben-bikmans-digital-ai-mind

📢 Dr. Bikman’s Community & Coaching Site: https://insuliniq.com

Topic: Retatrutide activates GLP-1, GIP, and glucagon receptors, combining appetite suppression with increased energy expenditure and powerful liver fat reduction. Dr. Bikman argues that its best use is not as a permanent shortcut, but as a tool to help people regain control over food habits and eventually reduce reliance on medication.

Summary: Dr. Ben Bikman explains retatrutide, a next-generation metabolic drug that activates three receptors at once: GLP-1, GIP, and glucagon. While semaglutide targets GLP-1 and tirzepatide targets GLP-1 plus GIP, retatrutide adds a third arm through glucagon receptor activation. This makes it distinct because GLP-1 and GIP mainly reduce food intake, while glucagon adds an energy-output effect by increasing fat oxidation, liver fat clearance, and energy expenditure.

Dr. Bikman focuses especially on glucagon because it is the novel feature of retatrutide. In the liver, glucagon stimulates fat burning, suppresses new fat production, promotes hepatic fat clearance, and increases energy expenditure through futile cycling and FGF21 signaling. Human trials show remarkable reductions in body weight and liver fat, with some studies reporting over 80% relative reductions in hepatic fat content and nearly 90% of treated participants reaching normal liver fat levels.

He also explains that glucagon receptors are not expressed on skeletal muscle, which means the drug’s glucagon arm should not directly signal muscle breakdown. Instead, the liver and fat tissue respond while muscle largely ignores the glucagon signal. The practical takeaway is that retatrutide may represent the next major step in incretin-based therapy, but Dr. Bikman emphasizes again that these drugs should ideally be used as a temporary tool—a crutch—to help people reduce cravings, relearn eating patterns, and ultimately rely less on medication over time.

References: For complete show notes and references, we invite you to become an Insider subscriber. You’ll enjoy real-time, livestream Metabolic Classroom access which includes live Q&A with Ben after the lecture, unlimited access to Dr. Bikman’s Digital Mind, ad-free podcast episodes, show notes and references, and Ben’s Weekly Research Review Podcast. Learn more: https://www.benbikman.com

Translation Notes: You can click the gear icon at the bottom of this video to auto-translate captions. For example, to translate into Polish, select Subtitles, choose Auto-Translate, then first choose English, then choose Auto-Translate again, then choose Polish.)

Also, Dr. Bikman’s Digital Mind can interact with you in many languages: https://benbikman.com/ben-bikmans-digital-ai-mind

In addition, our channel has access to YouTube’s innovative “auto-dubbing” feature. The process supports translations from English into many languages, with more to come. Click on the gear icon, then choose “Audio track” to access. (This availability is often delayed several weeks or more, so check back often.)

Timestamps (approximate): 00:50 — Introduction: Retatrutide and the Next Step in Metabolic Drugs 01:49 — From Semaglutide to Tirzepatide to Retatrutide 03:15 — Why Glucagon Activation Must Be Balanced 04:15 — GLP-1 and GIP: Appetite, Cravings, and Tolerability 06:21 — Why Glucagon Is the Novel Addition 07:19 — Where Glucagon Receptors Are Found 08:24 — Hepatic Futile Cycling and Energy Expenditure 10:18 — Amino Acid Catabolism and ATP Use 12:38 — Glucagon’s Effects on Fat Cells 16:34 — Why Muscle Does Not Respond to Glucagon 18:51 — Clinical Evidence: Weight Loss and Liver Fat Reduction 20:59 — Phase 3 Results and Cardiometabolic Improvements 23:18 — Best Use Case: A Tool to Relearn Eating Patterns 25:31 — Final Takeaways: The Triple-Agonist Advantage

NOTE: The information presented is not intended to be a substitute for professional medical…

Back to Ben Bikman · Report a problem